<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03769181</url>
  </required_header>
  <id_info>
    <org_study_id>ACT15320</org_study_id>
    <secondary_id>2018-002442-37</secondary_id>
    <secondary_id>U1111-1211-9010</secondary_id>
    <nct_id>NCT03769181</nct_id>
  </id_info>
  <brief_title>A Study of Isatuximab-based Therapy in Participants With Lymphoma</brief_title>
  <official_title>A Phase 1/2 Open-label, Multi-center, Safety, Preliminary Efficacy and Pharmacokinetic (PK) Study of Isatuximab in Combination With Other Anti-cancer Therapies in Participants With Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      Phase 1&#xD;
&#xD;
      -To characterize the safety and tolerability of isatuximab in combination with cemiplimab in&#xD;
      participants with relapsed and refractory classic Hodgkin's lymphoma (cHL), diffuse large&#xD;
      B-cell lymphoma (DLBCL) or peripheral T-cell lymphoma (PTCL), and to confirm the recommended&#xD;
      Phase 2 dose (RP2D).&#xD;
&#xD;
      Phase 2&#xD;
&#xD;
        -  Cohort A1 (anti-programmed cell death protein 1/ligand 1 [PD-1/PD-L1] naïve cHL): To&#xD;
           assess the complete remission (CR) rate of isatuximab in combination with cemiplimab.&#xD;
&#xD;
        -  Cohort A2 (cHL progressing from PD-1/PD-L1), B (DLBCL) and C (PTCL): To assess the&#xD;
           objective response rate (ORR) of isatuximab in combination with cemiplimab.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the safety of the RP2D of the combination of isatuximab with cemiplimab.&#xD;
&#xD;
        -  To evaluate the safety of the combination of isatuximab with cemiplimab and radiotherapy&#xD;
           in patients with cHL.&#xD;
&#xD;
        -  To evaluate the immunogenicity of isatuximab and cemiplimab when given in combination.&#xD;
&#xD;
        -  To characterize the pharmacokinetic (PK) profile of isatuximab and cemiplimab when given&#xD;
           in combination.&#xD;
&#xD;
        -  To assess overall efficacy of isatuximab in combination with cemiplimab and isatuximab&#xD;
           in combination with cemiplimab and radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration per patient is up to 28 months, including an up to 28-day screening&#xD;
      period, an up to 96-week treatment period, and a 90-day safety follow up period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2018</start_date>
  <completion_date type="Anticipated">October 24, 2022</completion_date>
  <primary_completion_date type="Actual">February 15, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1 - Dose limiting toxicities (DLTs); Recommended Phase 2 dose (RP2D)</measure>
    <time_frame>1st Cycle - 28 days</time_frame>
    <description>DLTs as observed during DLT-observation period; Dose selected for the Phase 2 portion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Cohort A1 (anti-PD-1/PD-L1 naive cHL): Complete Remission Rate</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The proportion of participants who have a Complete Remission as a best overall response during the isatuximab + cemiplimab therapy period using the Lugano response criteria 2014</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 2 - Cohort A2 (cHL progressing from PD-1/PD-L1), B (DLBCL) and C (PTCL): Response Rate</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The proportion of participants who have a Complete Response or Partial Response as a best overall response during isatuximab + cemiplimab therapy period using the Lugano response criteria 2014</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events (AEs)/Serious Adverse Events (SAEs) for isatuximab + cemiplimab</measure>
    <time_frame>Up to 90 days after last study treatment administration (Up to approximately 27 months after first study treatment administration)</time_frame>
    <description>Number of patients with AEs/SAEs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events/Serious Adverse Events for isatuximab + cemiplimab + radiotherapy</measure>
    <time_frame>Up to 90 days after last study treatment administration (Up to approximately 27 months after first study treatment administration)</time_frame>
    <description>Number of patients with AEs/SAEs in cohorts A1 and A2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity: Anti-drug antibody levels</measure>
    <time_frame>Up to 90 days following the last administration of study treatment or at the primary analysis cut-of date, whichever comes first</time_frame>
    <description>Anti-drug antibody (ADA) levels against isatuximab and against cemiplimab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: Cmax</measure>
    <time_frame>Up to 90 days following the last administration of study treatment or at the primary analysis cut-of date, whichever comes first</time_frame>
    <description>Maximum concentration observed after the first infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: Ctrough</measure>
    <time_frame>Up to 90 days following the last administration of study treatment or at the primary analysis cut-of date, whichever comes first</time_frame>
    <description>Concentrations observed just before treatment administration during repeated dosing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic evaluation: AUC0-T</measure>
    <time_frame>Up to 90 days following the last administration of study treatment or at the primary analysis cut-of date, whichever comes first</time_frame>
    <description>Area under the concentration versus time curve calculated using the trapezoidal method over the dosing interval (ie, 6 days for isatuximab or 21 days for cemiplimab)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor burden change</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The best percent-change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The sum of complete responses (CR) + partial responses (PR) + stable disease (SD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The time from the date of the first response (PR or CR in radiographic objective response) that is subsequently confirmed to the date of first confirmed disease progression or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>Up to 24 weeks after last patient treated in a given cohort</time_frame>
    <description>The time from the first study treatment administration to the date of first documentation of progressive disease or death, whichever comes first</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Phase 1: cHl/DLBCL/PTCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab dose 1 or 2 depending on dose limiting toxicities (DLTs) observed and cemiplimab predefined dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Isatuximab and cemiplimab combination: Isatuximab dose determined in Phase 1 part of study and cemiplimab predefined dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isatuximab SAR650984</intervention_name>
    <description>Pharmaceutical form: solution for infusion&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Phase 1: cHl/DLBCL/PTCL</arm_group_label>
    <arm_group_label>Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_label>Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor</arm_group_label>
    <arm_group_label>Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_label>Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <other_name>Sarclisa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cemiplimab REGN2810</intervention_name>
    <description>Pharmaceutical form: solution for infusion&#xD;
Route of administration: intravenous</description>
    <arm_group_label>Phase 1: cHl/DLBCL/PTCL</arm_group_label>
    <arm_group_label>Phase 2: Cohort A1: cHL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_label>Phase 2: Cohort A2: cHL, anti PD-1/PD-L1 progressor</arm_group_label>
    <arm_group_label>Phase 2: Cohort B: DLBCL, anti PD-1/PD-L1 naïve</arm_group_label>
    <arm_group_label>Phase 2: Cohort C: PTCL, anti PD-1/PD-L1 naïve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Participants must be ≥ 12 years of age inclusive, at the time of signing the informed&#xD;
             consent&#xD;
&#xD;
          -  Disease location amenable to tumor biopsy at baseline&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  For Cohort A1 (classic Hodgkin's lymphoma [cHL] anti-programmed cell death protein&#xD;
             1/ligand 1 [PD-1/PD-L1] inhibitor naïve): Histologically confirmed advanced cHL that&#xD;
             has relapsed or progressed after at least 3 lines of systemic therapy that may include&#xD;
             autologous hematopoietic stem cell transplant (auto-HSCT) or auto-HSCT and brentuximab&#xD;
             vedotin (BV)&#xD;
&#xD;
          -  For Cohort A2 (cHL anti-PD-1/PD-L1 inhibitor progressor): Histologically confirmed&#xD;
             advanced cHL which has relapsed or progressed after one previous anti-PD-1/PD-L1&#xD;
             containing regimen as the most recent prior therapy but no more than 4 lines of&#xD;
             previous chemotherapy including the anti-PD-1/PD-L1 containing regimen and&#xD;
             documentation of benefit during or after the anti-PD-1/PD-L1 containing regimen within&#xD;
             4 months prior to initiation of investigational medicinal product (IMP)&#xD;
&#xD;
          -  For Cohort B (diffuse large B-cell lymphoma [DLBCL]): Histologically confirmed&#xD;
             advanced DLBCL that has relapsed or progressed after 2 lines of systemic therapy&#xD;
             including auto-HSCT or 2 lines of systemic therapy for participants who are not&#xD;
             eligible for auto-HSCT&#xD;
&#xD;
          -  For Cohort C (peripheral T-cell lymphoma [PTCL]): Histologically confirmed advanced&#xD;
             PTCL that has relapsed or progressed after either first-line chemotherapy and&#xD;
             auto-HSCT as consolidation of first remission or first-line chemotherapy if&#xD;
             participants are ineligible for auto-HSCT&#xD;
&#xD;
          -  Body weight of &gt; 45 kg for patients with age &lt;18 years&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior exposure to agent that blocks CD38&#xD;
&#xD;
          -  For patients with cHL (PD-1/PD-L1 naïve), DLBCL or PTCL prior exposure to any agent&#xD;
             (approved or investigational) that blocks the PD-1/PD-L1, PD-L2, CD137, CTLA-4 or&#xD;
             LAG-3&#xD;
&#xD;
          -  Evidence of other immune related disease/conditions&#xD;
&#xD;
          -  Has received a live-virus vaccination within 28 days of planned treatment start;&#xD;
             seasonal flu vaccines that do not contain live virus are permitted&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≥2&#xD;
&#xD;
          -  Poor bone marrow reserve&#xD;
&#xD;
          -  Poor organ function&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigational Site Number :2500006</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500005</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500008</name>
      <address>
        <city>Marseille</city>
        <zip>13009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500004</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500002</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500007</name>
      <address>
        <city>Pessac</city>
        <zip>33600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500003</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :2500001</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800003</name>
      <address>
        <city>Rozzano</city>
        <state>Milano</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800002</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :3800006</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4100001</name>
      <address>
        <city>Gangnam-gu</city>
        <state>Seoul-teukbyeolsi</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :4100002</name>
      <address>
        <city>Seoul</city>
        <state>Seoul-teukbyeolsi</state>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :5280002</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :5280001</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6200002</name>
      <address>
        <city>Coimbra</city>
        <zip>3000-075</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6200004</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :6200003</name>
      <address>
        <city>Porto</city>
        <zip>4200</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240003</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240005</name>
      <address>
        <city>Barcelona</city>
        <state>Barcelona [Barcelona]</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240002</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <state>Castilla Y León</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :7240004</name>
      <address>
        <city>Madrid / Madrid</city>
        <state>Madrid, Comunidad De</state>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :1580002</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>September 27, 2021</verification_date>
  <study_first_submitted>November 29, 2018</study_first_submitted>
  <study_first_submitted_qc>December 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2018</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Anti-CD38 monoclonal antibody</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cemiplimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

